Literature DB >> 28756037

Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France.

P Tuppin1, J Rudant2, P Constantinou2, C Gastaldi-Ménager2, A Rachas2, L de Roquefeuil2, G Maura2, H Caillol2, A Tajahmady2, J Coste2, C Gissot2, A Weill2, A Fagot-Campagna2.   

Abstract

In 1999, French legislators asked health insurance funds to develop a système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) [national health insurance information system] in order to more precisely determine and evaluate health care utilization and health care expenditure of beneficiaries. These data, based on almost 66 million inhabitants in 2015, have already been the subject of numerous international publications on various topics: prevalence and incidence of diseases, patient care pathways, health status and health care utilization of specific populations, real-life use of drugs, assessment of adverse effects of drugs or other health care procedures, monitoring of national health insurance expenditure, etc. SNIIRAM comprises individual information on the sociodemographic and medical characteristics of beneficiaries and all hospital care and office medicine reimbursements, coded according to various systems. Access to data is controlled by permissions dependent on the type of data requested or used, their temporality and the researcher's status. In general, data can be analyzed by accredited agencies over a period covering the last three years plus the current year, and specific requests can be submitted to extract data over longer periods. A 1/97th random sample of SNIIRAM, the échantillon généraliste des bénéficiaires (EGB), representative of the national population of health insurance beneficiaries, was composed in 2005 to allow 20-year follow-up with facilitated access for medical research. The EGB is an open cohort, which includes new beneficiaries and newborn infants. SNIIRAM has continued to grow and extend to become, in 2016, the cornerstone of the future système national des données de santé (SNDS) [national health data system], which will gradually integrate new information (causes of death, social and medical data and complementary health insurance). In parallel, the modalities of data access and protection systems have also evolved. This article describes the SNIIRAM data warehouse and its transformation into SNDS, the data collected, the tools developed in order to facilitate data analysis, the limitations encountered, and changing access permissions.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Assurance Maladie; Consommation de soins; Epidemiology; France; French national health data system; Health care use; Health insurance; Système national d’information en santé; Épidémiologie

Mesh:

Year:  2017        PMID: 28756037     DOI: 10.1016/j.respe.2017.05.004

Source DB:  PubMed          Journal:  Rev Epidemiol Sante Publique        ISSN: 0398-7620            Impact factor:   1.019


  118 in total

1.  Identifying diabetes cases in health administrative databases: a validation study based on a large French cohort.

Authors:  Sonsoles Fuentes; Emmanuel Cosson; Laurence Mandereau-Bruno; Anne Fagot-Campagna; Pascale Bernillon; Marcel Goldberg; Sandrine Fosse-Edorh
Journal:  Int J Public Health       Date:  2018-12-04       Impact factor: 3.380

2.  Key considerations when using health insurance claims data in advanced data analyses: an experience report.

Authors:  Renata Konrad; Wenchang Zhang; Margrét Bjarndóttir; Ruben Proaño
Journal:  Health Syst (Basingstoke)       Date:  2019-03-01

3.  Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs.

Authors:  Pierre-Olivier Blotière; Fanny Raguideau; Alain Weill; Elisabeth Elefant; Isabelle Perthus; Véronique Goulet; Florence Rouget; Mahmoud Zureik; Joël Coste; Rosemary Dray-Spira
Journal:  Neurology       Date:  2019-06-12       Impact factor: 9.910

4.  Association between Hospitalization and Change of Frailty Status in the GAZEL Cohort.

Authors:  B Landré; P Aegerter; M Zins; M Goldberg; J Ankri; M Herr
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

5.  Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people.

Authors:  Laura Semenzato; Jérémie Botton; Jérôme Drouin; François Cuenot; Rosemary Dray-Spira; Alain Weill; Mahmoud Zureik
Journal:  Lancet Reg Health Eur       Date:  2021-07-16

6.  Teriflunomide-exposed pregnancies in a French cohort of patients with multiple sclerosis.

Authors:  Astrid Barataud-Reilhac; Sandrine Kerbrat; Jonathan Roux; Alice Guilleux; Elisabeth Polard; Emmanuelle Leray
Journal:  Neurol Clin Pract       Date:  2020-08

7.  Home blood pressure monitoring in France: Device possession rate and associated determinants, the Esteban study.

Authors:  Alexandre Vallée; Amélie Gabet; Clémence Grave; Hélène Lelong; Jacques Blacher; Valérie Olié
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-23       Impact factor: 3.738

8.  Inappropriate Use of Oral Antithrombotic Combinations in an Outpatient Setting and Associated Risks: A French Nationwide Cohort Study.

Authors:  Lorène Zerah; Dominique Bonnet-Zamponi; Aya Ajrouche; Jean-Philippe Collet; Yann De Rycke; Florence Tubach
Journal:  J Clin Med       Date:  2021-05-27       Impact factor: 4.241

Review 9.  Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network.

Authors:  Thomas Soeiro; Clémence Lacroix; Vincent Pradel; Maryse Lapeyre-Mestre; Joëlle Micallef
Journal:  Front Psychiatry       Date:  2021-05-17       Impact factor: 4.157

10.  Patterns of hypertension management in France in 2015: The ESTEBAN survey.

Authors:  Alexandre Vallée; Amélie Gabet; Clémence Grave; Emmanuel Sorbets; Jacques Blacher; Valérie Olié
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-02-24       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.